Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting
- 31 August 2009
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (4) , 627-632
Abstract
We have piloted a low-dose schedule of 5-azacytidine followed by donor lymphocyte infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic leukemia (CMMoL) after allografting. Of the 26 patients (median age 62 years, range 28–75) with relapsed AML (n=24) or CMMoL (n=2), 11 (42%) had poor-risk cytogenetics. Twenty-three patients had received fludarabine-based reduced-toxicity conditioning regimens, and three had received conventional myeloablative conditioning. Patients received 5-azacytidine s.c., at a total daily dose of 100 mg, on days 1–3, to be followed by DLI on day 10, with the next course of treatment to be started on day 22. A total of 60 courses of 5-azacytidine were administered, with a median of 2 courses (range: 1–10). In 44 courses, 5-azacytidine was followed by DLI, and thus 19/26 (73%) patients received at least one course of this combined treatment. Clinically relevant neutropenic infections not associated with progressive disease developed in four patients, one of them succumbing to sepsis. Only two patients developed de novo acute GvHD after the combination of 5-azacytidine and DLI. Overall, 66% of the patients benefited from this treatment, with continued CRs achieved in 4 (16%) patients, lasting a median of 525 days (range: 450+ to 820+), and a 50% rate of temporary disease control with stable mixed chimerism (median duration 72 days). The median survival from the start of 5-azacytidine treatment was 136 days (range: 23 to 873+), with an estimated 2-year survival probability of 16%. In conclusion, this non-intensive outpatient regimen of 5-azacytidine followed by DLI is feasible, with a very low aGVHD rate. Objective responses, including continuous complete donor chimerism, occurred also in patients with poor-risk cytogenetics.Keywords
This publication has 31 references indexed in Scilit:
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Donor lymphocyte infusions for acute myeloid leukaemiaBest Practice & Research Clinical Haematology, 2008
- A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantationBone Marrow Transplantation, 2008
- 5-AZA-2′-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man StoryCancer Research, 2007
- Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplantBone Marrow Transplantation, 2004
- Epigenetic targets in hematopoietic malignanciesOncogene, 2003
- 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?Blood, 2003
- Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly PatientsJournal of Clinical Oncology, 2000
- Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patientsBlood, 1990
- MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINEThe Lancet, 1984